A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome: two-year outcomes.

David G SweetMark TurnerZbyněk StraňákRichard PlavkaPaul ClarkeBen StensonDominique SingerRangmar GoelzLaura FabbriGuido VaroliAnnalisa PiccinnoDebora SantoroDorothea Del BuonoChristian P Speer

Published in: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2020)

This assessment offers reassurance that treatment with CHF5633 surfactant was not associated with adverse neurodevelopmental, respiratory, or health outcomes by two years corrected age.

Keyphrases

endothelial cells
gestational age
low birth weight
preterm birth
respiratory tract
induced pluripotent stem cells
case report
emergency department
clinical trial
pluripotent stem cells
type diabetes